Effect of Estrogen Replacement Therapy on Bladder Circulation in Old Female Rats by Hikita, Katsuya et al.
Yonago Acta medica 2004;47:81–89
Effect of Estrogen Replacement Therapy on Bladder 
Circulation in Old Female Rats 
Katsuya Hikita, Naoto Kobayashi and Ikuo Miyagawa
Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty 
of Medicine, Yonago 683-8504 Japan
The effect of estradiol (E2) on the urinary bladder of old female rats was investigated by 
examining the histology and blood flow in the bladders.  A total of 20 female Wister rats 
aged 16 months were divided into 4 groups:  Group I, 5 normal controls; Group II, 5 rats 
treated with E2 for 4 weeks; Group III, rats treated with E2 for 8 weeks; and Group IV, 
5 rats receiving a placebo for 8 weeks.  After the treatment, we removed the bladders, 
then weighed and stained them with hematoxylin and eosin.  The muscle content was 
analyzed with the Elastica-van Gieson method, and the number of blood vessels with the 
Massonʼs trichrome method.  Blood circulation in the bladders was also measured.  The 
E2-replaced groups showed higher levels than the other groups in terms of blood flow in 
the bladder (20.6 ± 1.8 mL/min for Group II and 23.4 ± 1.5 mL/min for Group III, both 
P < 0.05 versus Groups I and IV), muscle content (2.33 ± 0.47 and 3.11 ± 0.48 for Groups 
II and III, respectively, both P < 0.05 versus Groups I and IV) and bladder weight (185.3 
± 6.2 mg and 193.2 ± 23.5 mg for Groups II and III; Group III showed P < 0.05 ver-
sus Groups I and IV).  Differences in body weight and number of blood vessels among 
groups were not significant.  We observed an increase in blood circulation, muscle con-
tent and weight of the bladder:  E2-replacement therapy positively affected bladder func-
tions.  
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Urinary incontinence is one of the most difficult 
problems for elderly women to maintain a decent 
quality of life.  Such changes in bladder function 
are produced postmenopausally as detrusor insta-
bility, stress urinary incontinence and a propensity 
toward urinary tract infection:  the dysfunctions are 
attributed in part to estrogen deficiency (Stenberg et 
al., 1995; Thom and Brown, 1998).  The tissues of 
the lower urinary tract and pelvic floor are known 
to be estrogen-sensitive because estrogen receptors 
are located throughout the bladder and urethra (Ba-
tra and Iosif, 1983; Klutke and Bergman, 1995).  It 
is hypothesized that estrogen replacement therapy 
may be useful for urinary incontinence for several 
reasons.  In women with stress incontinence, estro-
gen might reverse the effects of urethral atrophy, 
improve coaptation and, therefore, increase ure-
thral closure pressure.  Because estrogen has also 
been linked in increasing the sensory threshold of 
the bladder to cholinergic stimulation, estrogen re-
placement therapy may be equally useful for treat-
ing detrusor instability (Ekstrom et al., 1993; Fantl 
et al., 1996).  To date, research on the success of 
estrogen replacement therapy for postmenopausal 
 Abbreviations:  E2, estradiol; HE, hematoxylin and eosin; NIH, National Institutes of Health 
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bladder dysfunction has been quite controversial 
because many studies were based on subjective 
reports.  More than 60 years ago, Salmon et al. 
(1941) reported successful treatment of postmeno-
pausal women with intramuscular estrogen therapy. 
Similar results have been reported elsewhere (Rud, 
1980).
        Animal studies have helped to shed light on 
the role of estrogen in bladder function.  Longhurst 
et al. (1992) found that estrogen treatment actually 
increases detrusor sensitivity and improves blad-
der constriction.  One study proposed that estro-
genic effects may also increase urethral blood flow 
(Batra and Iosif, 1983).  In that study, the effects 
were examined after several days of treatment with 
relatively high amounts of estrogen.  We decided 
to quantitatively assess the effect of long-term es-
trogen replacement on the smooth muscle, vesical 
vessels and blood flow, and muscle content of the 
bladder in old female rats.  
Materials and Methods
All animal experiments were performed in ac-
cordance with the Guidelines established by the 
Tottori University Committee for Animal Experi-
mentation.  We divided 20 female Wister rats aged 
16 months into 4 groups each with 5 animals.  A 
silastic tube (inside diameter = 2.5 mm, length = 
30 mm) (Kaneda Medix, Osaka, Japan) containing 
sesame oil (Kadoya, Tokyo, Japan) was subcutane-
ously inserted in the rats of 3 groups (not in the 
control group).  Ovariectomy was not performed 
in any group.  Group-I rats received no treatment 
(control group).  Group-II rats were administered 
2.50 mg of estradiol (E2) dissolved in sesame oil 
through a silastic tube for 4 weeks (4-week E2-
replaced group).  Group-III rats were E2-adminis-
tered for 8 weeks in the same manner as for Group 
II (8-week E2-replaced group).  Group-IV rats 
(placebo group) were treated only with sesame oil 
without E2 for 8 weeks by the same methods as for 
Groups II and III (Ohata, 2002).  All animals were 
kept in an air-conditioned room lighted 12 h a day, 
and allowed access to food and water ad libitum.
Measurement of plasma E2
Plasma E2 concentrations were assessed by radio-
immunoassay with a kit from SRL (Tokyo) when 
rats were 16 months old in Group I, 17 months old 
in Group II and 18 months old in Groups III and 
IV.  After the rats were anesthesized with subcu-
taneous injection of 1.0 g/kg urethane, an amount 
of blood (2.5 mL) was taken from the heart and 
placed in a cyclone separator to measure the plasma 
E2 concentration levels.  
Measurement of blood flow in the urinary 
bladder
We measured blood flow in the rat bladder with a 
laser Doppler flowmeter (BRL-100, Bioresearch, 
Nagoya, Japan).  After incision of the abdomen 
under anesthesia by subcutaneous injection of 1.0 
g/kg urethane, we identified the bladder, and emp-
tied and attached a probe to the dome of the blad-
der (Saito and Miyagawa, 2001) to measure blood 
flow for 5 min.  Data used were mean ± SE for 1 
min.  
Histological examination of the rat bladder 
After the animals were anesthetized with subcu-
taneous 1.0 g/kg urethane injection, the bladder 
was surgically removed from the surrounding tis-
sues and weighed.  Each bladder was transected 
at the urethra level, sectioned into sagital slices, 
immediately fixed with 10% formalin, and then 
embedded in paraffin.  From these paraffin blocks, 
10-µm-thick tissue sections were prepared in verti-
cal cross slices.  The tissue sections were deparaf-
finized with xylene, and rehydrated with a graded 
series of ethanol.  All specimens were stained ei-
ther with hematoxylin and eosin (HE), Elastica-van 
Gieson or Masson sʼ trichrome.  The Elastica-van 
Gieson method distinguishes the smooth muscle 
area density from the connective tissue area densi-
ty, staining smooth muscle yellow and collagen red. 
Each section was viewed under a light   microscope 
at a magnification of 400 times.  To analyze the ef-
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fect of estrogen replacement on the smooth muscle 
content, color-assisted quantitative image analysis 
was used with the Elastica-van Gieson method. 
The Masson sʼ trichrome method was applied to 
observe each section of blood vessels in the smooth 
muscle of the bladder linings.  Data were obtained 
from the 5 animals in each group and averaged. 
Color-assisted quantitative image analysis
The stained tissue sections were viewed under a 
microscope (BX50, Olympus, Tokyo).  The image 
of the histologic sections was displayed on a color 
monitor (PVM-20M4V, Sony, Tokyo) and printed 
with a digital color printer (CP700DSA, Mitsubi-
shi, Tokyo).  It was then digitized with a scanner 
(GT-8000, Epson, Tokyo) operated by a Macintosh 
Powerbook G3 (Apple Computer, Inc., Cupertino, 
CA), and automated image analysis was performed 
with National Institutes of Health (NIH) Image 1.55 
(Research Service Branch, NIH, Bethesda, MD). 
The NIH Image 1.55 system discriminates color 
differences in stained tissue sections:  We applied 
the system to discriminate differentially stained 
components of smooth muscle and connective tis-
sues, which were calculated per full screen.  At 
least 10 different fields were examined from each 
tissue section.  The ratio of smooth muscle area/
connective tissue area was determined for each 
animal.  
Statistical analysis  
Statistical significances of differences among 
groups were compared with analysis of variance 
(ANOVA) and Fisher sʼ multiple comparison test. 




Plasma E2 levels ranged from 7.5 to 28.3 pg/mL 
in Group I, 35.0 to 57.5 pg/mL in Group II, 35.0 to 
57.4 pg/mL in Group III and 9.9 to 19.7 pg/mL in 
Group IV.  Differences in plasma E2 levels were 
significant between all pairs of Groups, except be-
tween Groups I and IV (Table 1). 
Bladder and body weight
Bladder weight was significantly higher in Group 
III than in Groups I and IV.  Group II showed 
a higher tendency of mean bladder weight than 
Groups I and IV, but there was no statistical sig-
nificance (Table 1).  Differences in body weight 
were not significant among all groups, while E2-
supplied groups showed a lower tendency of mean 
body weight. 
Table 1.  Plasma E2 levels, Bladder weight and Body weight
 Group Plasma E2 levels (pg/mL) Bladder weight (mg) Body  weight (g)
 I 19.3 ± 8.4  164.5 ±   9.1 355.5 ± 32.0
 II 38.5 ± 6.1  185.3 ±   6.2  338.6 ± 27.0
 III 48.8 ± 9.1   193.2 ± 23.5 344.8 ± 34.2
 IV   13.9 ± 3.8   164.3 ± 14.0 349.7± 25.6
 Each value is mean ± SE.
* Significant difference; P < 0.05. 
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Blood fl ow and histological examination of 
the rat bladder
Blood fl ow levels of the bladder in Groups II and 
III were signifi cantly (P < 0.05) higher than in 
Groups I and IV.  A longer period of E2 supply 
showed an increasing tendency toward blood fl ow: 
blood fl ow level was higher in the 8-week-supplied 
Group III than the 4-week-supplied Group II (Table 
2).  The difference in number of blood vessels of 
the bladder was not signifi cant, but Groups II and 
III tended to show a higher number than Groups I 
and IV (Table 2). 
Table 2.  Blood fl ow and average number of blad-
der vessels  
 Group Blood fl ow (mL/min) Number of vessels
 I 16.6 ± 1.8 3.6 ± 1.1
 II 20.6 ± 1.8 4.8 ± 1.3
 III 23.4 ± 1.5 5.0 ± 1.2
 IV 18.2 ± 0.4 3.6 ± 1.3
 Each value is mean ± SE.
* Signifi cant difference; P < 0.05. 
Fig. 1.  Sections of rat bladders 
stained with the Massonʼs tri-
chrome method (original magnifi -
cation, × 400).   
 A: A control rat (Group I).
 B: A rat treated with E2 
  for 4 weeks (Group II).
 C: A rat treated with E2 
  for 8 weeks (Group III).
 D: A placebo rat (Group IV).
Figs. 1A and B on p. 84 
and 
Figs. 1C and D on p. 85
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Table 3.  Ratio of smooth muscle area/con nec-
tive tissue area
 Group    Smooth muscle area/connective tissue area
 I 1.45 ± 0.39 
 II 2.33 ± 0.47
 III 3.11 ± 0.48
 IV 1.14 ± 0.08
 Each value is mean ± SE.
* Signifi cant difference; P < 0.05. 
Figs. 1C and D.  
Legends, see the previous page. 
        The area density of the bladder was compared 
between smooth muscles and connective tissues. 
The 18-month-old placebo group (Group IV) 
showed a lower tendency of smooth muscle area 
than the 16-month-old control group (Group I). 
The increase in smooth muscle area density was 
signifi cant (P < 0.05 both) in E2-supplied Groups 
II and III compared to Groups I and IV, and the 
increase was signifi cantly higher (P < 0.05) in the 
8-week-supplied Group III than in the 4-week-
supplied Group II (Table 3).  Examples of bladder 
specimens are shown in Figs. 1 and 2.
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Past experiments in both humans and animals have 
shown that estrogen receptors are present in the 
urethra and bladder.  Estrogen infl uences lower 
urinary tract function and continence with various 
mechanisms:  estrogen increases cell activity in the 
bladder and urethra, increases blood fl ow in the 
urethral submucosa and urethral sphincter, sensi-
Fig. 2.  Sections of rat bladders 
stained with the Elastica-van Gie-
son method (original magnifi ca-
tion, × 400).
 A: A control rat (Group I).
 B: A rat treated with E2 
  for 4 weeks (Group II).
 C: A rat treated with E2 
  for 8 weeks (Group III).
 D: A placebo rat (Group IV).
Figs. 2A and B on p. 86 
and 
Figs. 2A and D on p. 87
tizes urethral sphincter α-adrenargic receptors and 
stimulates periurethral connective tissue metabo-
lism (Screiter et al., 1976; Versi and Cardozo, 1986; 
Bergman et al., 1990; Blakeman et al., 1996; Jack-
son et al., 1996).  
        We studied the effects of estrogen replacement 
therapy on mature rats whose estrous cycles have 
discontinued.  Our specifi c attention was paid to 
any result of estrogen replacement therapy:  bladder 
changes in blood fl ow, number of blood vessels, tis-
sues and weight.  Furthermore, to study the effects of 
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the duration of estrogen replacement, estrogen was 
introduced for 4 or 8 weeks to 2 different groups 
for any consequence stemming from longer dura-
tion of treatment.  
        We observed plasma E2 levels lower than 15 
pg/mL in Group IV.  The fertility period of rats 
lasts approximately until the age of 15 months, at 
which time the estrous cycle ceases (Handa et al., 
1987; Shulman et al., 1987; Albert et al., 1991). 
According to Albert et al. (1991), rats with normal 
body weights maintain the plasma E2 level slightly 
below the mean of 15 pg/mL throughout the estrous 
cycle.  In the present study, we gave no estrogen re-
placement to Groups I and IV.  The plasma E2 lev-
els obtained from 16-month-old rats in Group I ex-
ceeded 15 pg/mL, slightly higher than expected at 
such an age.  In Group IV, as expected, 18-month-
old ratsʼ levels were slightly lower than 15 pg/mL. 
Groups II and III received estrogen replacement, 
and their plasma E2 levels were signifi cantly in-
creased to more than 30 pg/mL and 40 pg/mL, re-
spectively.  Therefore, our E2-replacement method 
Figs. 2C and D.  
Legends, see the previous page. 
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provided adequate levels for studying its effects on 
rat bladders.  
        In a comparison to normal control rats, ovari-
ectomized rats had a decreased bladder weight 
and increased body weight (Longhurst et al., 
1992).  Also in our observations, we found that 
bladder weight was significantly heavier in Group 
III than Groups I and IV, while there were no sig-
nificant differences in Group II compared to the 
other groups.  However, Group II had a higher ten-
dency of mean bladder weight than Groups I and 
IV.  Thus, the bladder tended to gain weight when 
the E2 level was increased, which suggests that 
E2 replacement after menopause increases blad-
der weight.  The bladder had been thought to gain 
weight in muscle content and epithelium thickness 
(Rocha et al., 2002).  We observed no significant 
difference in mean body weight among groups, 
but estrogen-replaced rats lost some weight.  The 
mechanism for how estrogen protects the bladder 
against collagen formation is not yet known.  Some 
evidence suggests it has a cardioprotective action 
preferably through nitric oxide from endothelial 
release:  estrogen replacement may prevent the pro-
liferation of fibroblasts and collagen deposition in 
the blood vessels of the heart (Blacher et al., 2000). 
Whether a similar mechanism exists in the bladder 
is a subject of further study.
        The number of blood vessels influences intra-
urethral pressure (Versi and Cardozo, 1986).  Estro-
gen replacement therapy was reported to increase 
the number of periurethral and bladder vessels (Ma-
deiro et al., 2001).  In ovariectomized rats, how-
ever, the number of bladder vessels was decreased 
(Rocha et al., 2002).  We observed no significant 
differences in the number of bladder vessels among 
groups, but only a little increase in Groups II and 
III.  Estrogen acts directly on the number of bladder 
vessels in the urethra and periurethral tissue.  This 
action could explain the increase in the number of 
bladder vessels due to estrogen replacement.  Even 
with estrogen replacement, however, the increase 
in the number of bladder blood vessels was slight 
in our experiments:  the increase in muscle content 
and cell cycle activity might have acted together.  
        Estrogen treatment inhibits tissue weight gain 
and cardiac output, and so blood flow of the uri-
nary tract is also increased by estrogen (Batra et 
al., 1985, 1986).  In this study, there was a signifi-
cant difference in blood flow between E2-replaced 
groups and the control and placebo groups.  Es-
trogen increases blood flow as previously reported 
(Batra et al., 1986) as well as in the present study. 
The slight increase in bladder blood flow we ob-
served may be due to the increase in bladder weight 
and overall blood volume (not measured in the 
present study).  According to the literature, the 
compliance functions of the bladder and urinary 
pressure are also improved with estrogen.  These 
improved functions also help improve circulation 
(Fleischmann et al., 2002).  Our estrogen replace-
ment therapy for mature rats resulted in an increase 
in bladder muscle content and blood circulation, 
similarly as reported (Rocha et al., 2002). 
        In medical trials conducted since the 1960s 
predominantly in the United States, menopausal 
women have been given progesterone concurrently 
with estrogen to protect against increased risks of 
cancer.  Studies in Japan have also shown estro-
gen useful in the treatment of stress incontinence 
(Suzuki et al., 1997).  Since the present study has 
shown the benefits and advance effects of estrogen 
replacement therapy in rats, it should be advocated 
as a treatment in general practice.
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